UMIN-CTR Clinical Trial

Recruitment status Completed
Unique ID issued by UMIN UMIN000010227
Receipt No. R000011974
Official scientific title of the study Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin for HER2-positive operable breast cancer: KBOG-1204 trial
Date of disclosure of the study information 2013/03/12
Last modified on 2018/08/03 (Ver. 5)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Official scientific title of the study Multicenter phase II trial of neoadjuvant chemotherapy with trastuzumab, docetaxel, and carboplatin for HER2-positive operable breast cancer: KBOG-1204 trial
Title of the study (Brief title) Neoadjuvant TCbH therapy for HER2-positive breast cancer: KBOG-1204 trial
Region
Japan

Condition
Condition breast cancer
Classification by specialty
Breast surgery
Classification by malignancy Malignancy
Genomic information NO

Objectives
Narrative objectives1 Efficacy (histopathological response)
Basic objectives2 Safety,Efficacy
Basic objectives -Others
Trial characteristics_1 Exploratory
Trial characteristics_2 Pragmatic
Developmental phase Phase II

Assessment
Primary outcomes Pathological complete response rate
Key secondary outcomes Cardiac adverse events, Breast-conserving rate, Clinical response rate, Relapse-free survival, Overall survival

Base
Study type Interventional

Study design
Basic design Single arm
Randomization Non-randomized
Randomization unit
Blinding Open -no one is blinded
Control Uncontrolled
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms 1
Purpose of intervention Treatment
Type of intervention
Medicine
Interventions/Control_1 Neoaduvant chemotherapy with Docetaxel+Carboplatin+Trastuzumab
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit
80 years-old >
Gender Female
Key inclusion criteria 1) invasive breast cancer by needle biopsy
2) operable primary breast cancer
3) HER2 positive (IHC 3+ or FISH +)
4) ER, PgR known
5) P.S. = 0~1
6) measurable lesions
7) preserving the functions of bone marrow, heart, liver, and kidney
8) written informed consent
Key exclusion criteria 1) drug allergy
2) severe complications (malignant hypertension, congestive heart failure, coronary heart disease, myocardial infarction (onset within 6 months), arrhythmia (treated), infectious disease, bleeding tendency, etc)
3) feber, infection
4) peripheral neuropathy
5) pleural effusion, pericardial effusion
6) active double cancer
7) inflammatory breast cancer
8) bilateral breast cancer, male breast cancer
9) pregnancy
10) severe edema
11) interstitial pneumonia, fibrous lung disease
12) steroid-using patients
13) psychosomatic disease
14) unsuitable patients
Target sample size 40

Research contact person
Name of lead principal investigator Koichiro Tsugawa, M.D.
Organization St. Marianna University School of Medicine
Division name Department of Surgery, Division of Breast and Endocrine Surgery
Address 2-16-1, Sugao, Miyamae-ku, Kawasaki-city, Kanagawa, Japan
TEL 044-977-8111
Email koitsuga@marianna-u.ac.jp

Public contact
Name of contact person Yasuyuki Kojima, M.D.
Organization St. Marianna University School of Medicine
Division name Department of Surgery, Division of Breast and Endocrine Surgery
Address 2-16-1, Sugao, Miyamae-ku, Kawasaki-city, Kanagawa, Japan
TEL 044-977-8111
Homepage URL
Email kojiyasu@marianna-u.ac.jp

Sponsor
Institute Kanagawa Breast Oncology Group (KBOG)
Institute
Department

Funding Source
Organization Kanagawa Breast Oncology Group (KBOG)
Organization
Division
Category of Funding Organization Other
Nationality of Funding Organization Japan

Other related organizations
Co-sponsor
Name of secondary funder(s)

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions 東海大学付属病院、聖マリアンナ医科大学病院、聖マリアンナ医科大学附属ブレスト&イメージングセンター、横浜市立大学附属市民総合医療センター、北里大学病院、神奈川県立がんセンター、大船中央病院、横浜労災病院、湘南記念病院、みなと赤十字病院、横浜旭中央総合病院、東海大学付属八王子病院、横浜市立大学附属病院

Other administrative information
Date of disclosure of the study information
2013 Year 03 Month 12 Day

Progress
Recruitment status Completed
Date of protocol fixation
2012 Year 12 Month 17 Day
Anticipated trial start date
2013 Year 03 Month 13 Day
Last follow-up date
2015 Year 06 Month 30 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Related information
URL releasing protocol
Publication of results Unpublished
URL releasing results
Results
Other related information

Management information
Registered date
2013 Year 03 Month 12 Day
Last modified on
2018 Year 08 Month 03 Day


Link to view the page
URL(English) https://upload.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000011974